Ashley J Ferira1, Emma M Laing1, Dorothy B Hausman1, Daniel B Hall1, George P McCabe1, Berdine R Martin1, Kathleen M Hill Gallant1, Stuart J Warden1, Connie M Weaver1, Munro Peacock1, Richard D Lewis1. 1. Departments of Foods and Nutrition (A.J.F., E.M.L., D.B.Hau., and R.D.L.) and Statistics (D.B.Hal.), The University of Georgia, Athens, Georgia 30602; Departments of Nutrition Science (C.M.W., B.R.M., K.M.H.G.) and Statistics (G.P.M.), Purdue University, West Lafayette, Indiana 47907; Department of Medicine (M.P.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Physical Therapy (S.J.W.), Indiana University School of Health and Rehabilitation Sciences, Indianapolis, Indiana 46202.
Abstract
CONTEXT: Vitamin D supplementation trials with diabetes-related outcomes have been conducted almost exclusively in adults and provide equivocal findings. OBJECTIVE: The objective of this study was to determine the dose-response of vitamin D supplementation on fasting glucose, insulin, and a surrogate measure of insulin resistance in white and black children aged 9–13 years, who participated in the Georgia, Purdue, and Indiana University (or GAPI) trial: a 12-week multisite, randomized, triple-masked, dose-response, placebo-controlled vitamin D trial. DESIGN:Black and white children in the early stages of puberty (N = 323, 50% male, 51% black) were equally randomized to receive vitamin D3 (0, 400, 1000, 2000, or 4000 IU/day) for 12 weeks. Fasting serum 25-hydroxyvitamin D (25(OH)D), glucose and insulin were assessed at baseline and weeks 6 and 12. Homeostasis model assessment of insulin resistance was used as a surrogate measure of insulin resistance. Statistical analyses were conducted as intent-to-treat using a mixed effects model. RESULTS:Baseline serum 25(OH)D was inversely associated with insulin (r = −0.140, P = 0.017) and homeostasis model assessment of insulin resistance (r = −0.146, P = 0.012) after adjusting for race, sex, age, pubertal maturation, fat mass, and body mass index. Glucose, insulin, and insulin resistance increased (F > 5.79, P < .003) over the 12 weeks, despite vitamin D dose-dependent increases in serum 25(OH)D. CONCLUSIONS: Despite significant baseline inverse relationships between serum 25(OH)D and measures of insulin resistance, vitamin D supplementation had no impact on fasting glucose, insulin, or a surrogate measure of insulin resistance over 12 weeks in apparently healthy children.
RCT Entities:
CONTEXT: Vitamin D supplementation trials with diabetes-related outcomes have been conducted almost exclusively in adults and provide equivocal findings. OBJECTIVE: The objective of this study was to determine the dose-response of vitamin D supplementation on fasting glucose, insulin, and a surrogate measure of insulin resistance in white and black children aged 9–13 years, who participated in the Georgia, Purdue, and Indiana University (or GAPI) trial: a 12-week multisite, randomized, triple-masked, dose-response, placebo-controlled vitamin D trial. DESIGN: Black and white children in the early stages of puberty (N = 323, 50% male, 51% black) were equally randomized to receive vitamin D3 (0, 400, 1000, 2000, or 4000 IU/day) for 12 weeks. Fasting serum 25-hydroxyvitamin D (25(OH)D), glucose and insulin were assessed at baseline and weeks 6 and 12. Homeostasis model assessment of insulin resistance was used as a surrogate measure of insulin resistance. Statistical analyses were conducted as intent-to-treat using a mixed effects model. RESULTS: Baseline serum 25(OH)D was inversely associated with insulin (r = −0.140, P = 0.017) and homeostasis model assessment of insulin resistance (r = −0.146, P = 0.012) after adjusting for race, sex, age, pubertal maturation, fat mass, and body mass index. Glucose, insulin, and insulin resistance increased (F > 5.79, P < .003) over the 12 weeks, despite vitamin D dose-dependent increases in serum 25(OH)D. CONCLUSIONS: Despite significant baseline inverse relationships between serum 25(OH)D and measures of insulin resistance, vitamin D supplementation had no impact on fasting glucose, insulin, or a surrogate measure of insulin resistance over 12 weeks in apparently healthy children.
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Giuseppe Saggese; Francesco Vierucci; Flavia Prodam; Fabio Cardinale; Irene Cetin; Elena Chiappini; Gian Luigi De' Angelis; Maddalena Massari; Emanuele Miraglia Del Giudice; Michele Miraglia Del Giudice; Diego Peroni; Luigi Terracciano; Rino Agostiniani; Domenico Careddu; Daniele Giovanni Ghiglioni; Gianni Bona; Giuseppe Di Mauro; Giovanni Corsello Journal: Ital J Pediatr Date: 2018-05-08 Impact factor: 2.638
Authors: Kumaravel Rajakumar; Charity G Moore; Arshad T Khalid; Abbe N Vallejo; Mohamed A Virji; Michael F Holick; Susan L Greenspan; Silva Arslanian; Steven E Reis Journal: Am J Clin Nutr Date: 2020-04-01 Impact factor: 7.045
Authors: Andrea J Lobene; Joseph M Kindler; Nathan T Jenkins; Norman K Pollock; Emma M Laing; Arthur Grider; Richard D Lewis Journal: J Nutr Date: 2017-06-07 Impact factor: 4.798
Authors: Joseph M Kindler; Norman K Pollock; Emma M Laing; Assaf Oshri; Nathan T Jenkins; Carlos M Isales; Mark W Hamrick; Ke-Hong Ding; Dorothy B Hausman; George P McCabe; Berdine R Martin; Kathleen M Hill Gallant; Stuart J Warden; Connie M Weaver; Munro Peacock; Richard D Lewis Journal: J Bone Miner Res Date: 2017-07 Impact factor: 6.741
Authors: L M Coheley; J M Kindler; E M Laing; A Oshri; K M Hill Gallant; S J Warden; M Peacock; C M Weaver; R D Lewis Journal: Osteoporos Int Date: 2018-04-30 Impact factor: 4.507
Authors: Silvia Savastio; Erica Pozzi; Francesco Tagliaferri; Roberta Degrandi; Roberta Cinquatti; Ivana Rabbone; Gianni Bona Journal: Int J Mol Sci Date: 2020-05-16 Impact factor: 5.923